NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 63 resultados LastUpdate Última actualización 20/01/2022 [08:41:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   por página


Pharmaceutical Composition for Treating B-Cell Lymphoma

NºPublicación: US2022008425A1 13/01/2022

Solicitante:

FUNDAN UNIV SHANGHAI CANER CENTER [CN]

JP_2021532168_A

Resumen de: US2022008425A1

The present invention discloses a pharmaceutical composition for treating B-cell lymphoma, including a PI3K/AKT signaling pathway inhibitor and a chemotherapeutic drug, and further including a monoclonal antibody targeting CD20, such as rituximab. The pharmaceutical composition provided by the present invention is particularly suitable for the treatment of relapsed/refractory B-cell lymphoma. Given the critical role of cancer stem cells (CSCs) in the process of metastasis and drug resistance, the present invention proposes a new pro-differentiation therapy (PDT) strategy to cope with CSCs, i.e., to determine the decisive signaling pathway that maintains stem cell sternness and then promotes CSC differentiation by interfering with the pathway. Differentiated cells are eventually sensitive to conventional therapies, such as chemotherapy. In this situation, the PI3K/AKT signaling pathway inhibitor in combination with an R-CHOP regimen has a good effect on the treatment of drug-resistant diffuse large B-Cell lymphoma (DLBCL).

traducir

Anti-Human CD52 Immunoglobulins

NºPublicación: US2022010024A1 13/01/2022

Solicitante:

GENZYME CORP [US]

US_2020040091_A1

Resumen de: US2022010024A1

The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.

traducir

INHIBITORS OF BRUTON'S TYROSINE KINASE

NºPublicación: US2022008424A1 13/01/2022

Solicitante:

PHARMACYCLICS LLC [US]

MX_2019012657_A

Resumen de: US2022008424A1

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

traducir

COMBINED TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

NºPublicación: US2022008513A1 13/01/2022

Solicitante:

FOND CENTRO SAN RAFFAELE [IT]

CN_113597304_A

Resumen de: US2022008513A1

The present invention refers to the combination of an R-CHOP therapy with an administration of NGR-hTNF or an analog thereof for the treatment of primary central nervous system lymphoma, preferably relapsed/refractory primary central nervous system lymphoma.

traducir

COMBINATION THERAPY WITH NOTCH AND PD-1 OR PD-L1 INHIBITORS

NºPublicación: US2022008432A1 13/01/2022

Solicitante:

LILLY CO ELI [US]

Resumen de: US2022008432A1

The present invention provides medicaments for use in treating and methods of treating T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, erythroleukemia, triple negative breast cancer, breast cancer, ovarian cancer, melanoma, Sung cancer, non small-cell lung cancer, pancreatic cancer, glioblastoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, oral squamous cell carcinoma, skin cancer, medul!ob!astoma, hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, desmoid tumor, soft tissue sarcoma, or adenoid cystic carcinoma in a patient comprising combination therapy with 4,4,4-tri-fluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyemyl)-6-oxo-7H-pyrido[23-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyljbutanamide, or a pharmaceutically acceptable salt or hydrate thereof, and a PD-1 or a PD-L1 inhibitor selected from pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab.

traducir

METHODS OF DOSING ENGINEERED T CELLS FOR THE TREATMENT OF B CELL MALIGNANCIES

NºPublicación: US2022008465A1 13/01/2022

Solicitante:

JUNO THERAPEUTICS INC [US]

Resumen de: US2022008465A1

Provided are methods for treatment and uses involving the administration of doses of engineered T cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The engineered cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL). In some embodiments, the subject is within a particular range of age, such as subjects that are 25 years or less of age, such as pediatric subjects.

traducir

METHODS OF TREATING MULTIPLE MYELOMA CANCERS EXPRESSING HIGH LEVELS OF EPO-RECEPTOR USING PSA-EPO

NºPublicación: US2022008544A1 13/01/2022

Solicitante:

LIPOXEN TECH LIMITED [GB]

Resumen de: US2022008544A1

The present invention demonstrates that erythropoietin (EPO)-receptor (EPOR) is a malignant myeloma biomarker of sensitivity to EPO treatment and, itself a target for myeloma treatment. A low EPOR level in a myeloma cells of the subject indicates non-response to EPO treatment. Patients having high EPOR level in myeloma cells can be effectively treated with EPO, in particular an EPO derivatized with polysialic acid.

traducir

ANALOGUES AND DERIVATIVES OF CEPHALOTAXINE AND METHODS FOR MAKING AND USING THE COMPOUNDS

NºPublicación: US2022009944A1 13/01/2022

Solicitante:

UNIV OREGON STATE [US]

Resumen de: US2022009944A1

Disclosed herein are embodiments of a compound having a Formula Ior a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. Also disclosed are derivative compounds made from the compound of Formula I. Certain derivative compounds have a Formula V-2, or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof.Also disclosed are method for making and using the disclosed compounds. Certain disclosed embodiments are useful for treating and/or preventing certain diseases and/or disorders, including proliferation diseases, such as leukemia.

traducir

METHODS OF TREATING FLT3-MUTATED HEMATOLOGIC CANCERS

NºPublicación: US2022008448A1 13/01/2022

Solicitante:

CTI BIOPHARMA CORP [US]
OHIO STATE INNOVATION FOUNDATION [US]

WO_2020072544_PA

Resumen de: US2022008448A1

Methods to inhibit FLT3 activity in a subject or a cell with an FLT3 mutation are provided. Methods of treating a hematologic cancer, such as acute myeloid leukemia, in a subject identified as having an FLT3 mutation, are also provided.

traducir

T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof

NºPublicación: US2022008467A1 13/01/2022

Solicitante:

CUE BIOPHARMA INC [US]

WO_2020132366_PA

Resumen de: US2022008467A1

The present disclosure provides T-cell modulatory multimeric polypeptide epitope conjugates comprising an immunomodulatory polypeptide (“MOD”) that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide (“Co-MOD”) and a conjugated Wilms tumor-1 (WT-1) epitope presenting peptide. The T-Cell-MMP-epitope conjugates are useful for modulating the activity of a T-cell by delivering immunomodulatory peptides, such as IL-2 or IL-2 variants that exhibit reduced binding affinity for IL-2R, to the T-cells in a WT-1 epitope selective/specific manner, and accordingly, for treating individuals, particularly those with acute myeloid leukemia, myeloma, ovarian cancer, pancreatic cancer, non-small cell lung cancer, colorectal cancer, breast cancer, Wilms tumor, mesothelioma, soft tissue sarcoma, neuroblastoma, or nephroblastoma.

traducir

METHOD AND COMPOSITION EMBODIMENTS FOR TREATING ACUTE MYELOID LEUKEMIA

NºPublicación: US2022000880A1 06/01/2022

Solicitante:

RIGEL PHARMACEUTICALS INC [US]

Resumen de: US2022000880A1

Disclosed herein are embodiments of a method and pharmaceutical composition for treating acute myeloid leukemia (AML). In particular, the method embodiments comprise treating AML with 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one, or a prodrug thereof, alone or in combination with one or more therapeutic agents that themselves are effective for treating AML. Also disclosed are embodiments of a pharmaceutical composition comprising 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one, or a prodrug thereof, either as the sole therapeutic agent or in combination with one or more therapeutic agents effective for treating AML.

traducir

CHROMOSOME CONFORMATION MARKERS OF PROSTATE CANCER AND LYMPHOMA

NºPublicación: AU2021286283A1 06/01/2022

Solicitante:

OXFORD BIODYNAMICS PLC

AU_2021286282_A1

Resumen de: AU2021286283A1

A process for analysing chromosome regions and interactions relating to prognosis of prostate cancer or DLBCL. See Fig. 5.

traducir

CHROMOSOME CONFORMATION MARKERS OF PROSTATE CANCER AND LYMPHOMA

NºPublicación: AU2021286282A1 06/01/2022

Solicitante:

OXFORD BIODYNAMICS PLC

AU_2021286283_A1

Resumen de: AU2021286282A1

A process for analysing chromosome regions and interactions relating to prognosis of prostate cancer or DLBCL. See Fig. 5.

traducir

Pharmaceutical formulations of bi-specific diabodies and use of the same

NºPublicación: AU2020291508A1 06/01/2022

Solicitante:

MACROGENICS INC

TW_202112355_A

Resumen de: AU2020291508A1

The present invention is directed to stable aqueous pharmaceutical formulations that comprise a bispecific monovalent diabody ("Diabody formulation"), and to aqueous stabilizer solutions for stabilizing and administering said diabody. The invention particularly concerns such pharmaceutical formulations that comprise a diabody drug product (DART- A DP formulations) that comprise a sequence-optimized CD 123 x CDS bispecific diabody (DART- A) that is capable of simultaneously binding to CD 123 and CDS. The invention further concerns the use of such DART- A DP formulations in the treatment of hematologic malignancies such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients.

traducir

Immunotherapeutic compositions for treatment of glioblastoma multiforme

NºPublicación: AU2020284629A1 06/01/2022

Solicitante:

VARIATION BIOTECHNOLOGIES INC

Resumen de: AU2020284629A1

The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM), e.g., compositions comprising virus-like particles (VLPs) comprising Moloney Murine leukemia virus (MMLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with GM-CSF, which, at dose of at least 10 pg gB/pp65Gag, reverse dysregulation of anti-HCMV immunity in GBM patients.

traducir

TARGETING PLECKSTRIN-2 FOR TREATING CANCER

NºPublicación: US2022001018A1 06/01/2022

Solicitante:

UNIV NORTHWESTERN [US]

WO_2020092950_PA

Resumen de: US2022001018A1

Disclosed herein are compounds, compositions, and methods for treating cell proliferative diseases and disorders based on present inventors discovery that Pleckstrin-2 (Plek2) can be targeted to treat cell proliferative diseases and disorders. The compositions and methods disclosed herein include or utilize the disclosed compounds as therapeutic agents which inhibit the biological activity or expression of Pleckstrin-2 (Plek2) and collectively may be referred to as “Plek2 inhibitors.” Disclosed are small molecule inhibitors of Plek2 biological activity. The compositions and method may be utilized for treating cell proliferative diseases and disorders that are characterized by elevated levels of Plek2 expression and/or by activation of the phosphatidylinositide 3-kinase (PI3K)/Akt pathway. Cell proliferative diseases and disorders that may be treated using the disclosed compositions and methods may include, but not limited to, myeloproliferative neoplasms (MPNs) such as Philadelphia (Ph)-negative MPNs, and cancers such as acute myeloid leukemia (AML) and cancers characterized by solid tumors.

traducir

INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7)

NºPublicación: US2022000890A1 06/01/2022

Solicitante:

SYROS PHARMACEUTICALS INC [US]

AU_2019209475_A1

Resumen de: US2022000890A1

The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).

traducir

TUMOR MICROENVIRONMENT-BASED METHODS FOR ASSESSING CAR-T AND OTHER IMMUNOTHERAPIES

NºPublicación: US2022005551A1 06/01/2022

Solicitante:

BOSTONGENE CORP [US]

Resumen de: US2022005551A1

Aspects of the disclosure relate to methods for determining whether or a subject is likely to respond to certain adoptive cell therapies (e.g., chimeric antigen receptor (CAR) T-cell therapy, etc.). In some embodiments, the methods comprise the steps of identifying a subject as having a tumor microenvironment (TME) type based upon a molecular-functional (MF) expression signature of the subject, and determining whether or not the subject is likely to respond to a chimeric antigen receptor (CAR) T-cell therapy based upon the TME type. In some embodiments, the methods comprise determining the lymphoma microenvironment (LME) type of a lymphoma (e.g., Diffuse Large B cell lymphoma (DLBCL)) subject and identifying the subject's prognosis based upon the LME type determination.

traducir

METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS

NºPublicación: US2022003749A1 06/01/2022

Solicitante:

CELGENE CORP [US]

JP_2019216716_A

Resumen de: US2022003749A1

Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.

traducir

MULTIMERIC IL-15 SOLUBLE FUSION MOLECULES AND METHODS OF MAKING AND USING SAME

NºPublicación: US2022002383A1 06/01/2022

Solicitante:

ALTOR BIOSCIENCE LLC [US]

EP_3851459_A1

Resumen de: US2022002383A1

The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).

traducir

METHODS OF DETECTING A POLYPEPTIDE HAVING ANAPLASTIC LYMPHOMA KINASE ACTIVITY IN KIDNEY CANCER

NºPublicación: US2022003771A1 06/01/2022

Solicitante:

CELL SIGNALING TECHNOLOGY INC [US]

US_2020363417_A1

Resumen de: US2022003771A1

The invention provides methods to identify, diagnose, and treat kidney cancer through the detection of expression and/or activity of anaplastic lymphoma kinase (ALK). The detection of the presence of a polypeptide with ALK kinase activity (e.g., by detecting expression and/or activity of the polypeptide), identify those kidney cancers that are likely to respond to an ALK-inhibiting therapeutic.

traducir

BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA

NºPublicación: US2022002427A1 06/01/2022

Solicitante:

ENGMAB SARL [CH]

MX_2019004621_A

Resumen de: US2022002427A1

The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3ε (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma.

traducir

Genetically Modified Mice and Engraftment

NºPublicación: US2022000084A1 06/01/2022

Solicitante:

REGENERON PHARMA [US]
UNIV YALE [US]
INSTITUTE FOR RES IN BIOMEDICINE IRB [CH]

JP_2020092712_A

Resumen de: US2022000084A1

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

traducir

APPLICATION OF CHIDAMIDE

NºPublicación: US2022000848A1 06/01/2022

Solicitante:

SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD [CN]

Resumen de: US2022000848A1

The present application relates to the technical field of medicine, and discloses an application of Chidamide. The present application provides for the application of a therapeutic schedule for using Chidamide in the treatment of B cell lymphoma, and verifies by clinical test the outstanding effect of Chidamide monotherapy for diffuse large B cell lymphoma and recurrent or refractory follicular lymphoma accompanied by specific epigenetic regulation gene mutation. The application can treat B cell lymphoma patients more effectively.

traducir

GENE EXPRESSION PROFILES FOR B-CELL LYMPHOMA AND USES THEREOF

Nº publicación: US2022002814A1 06/01/2022

Solicitante:

PROVINCIAL HEALTH SERVICES AUTHORITY [CA]

CA_3115804_PA

Resumen de: US2022002814A1

The present invention relates to gene expression profiles for B-cell lymphoma. More specifically, the present invention relates to gene expression profiles for diagnosis, prognosis or therapy selection for an aggressive B-cell lymphoma.

traducir

Página1 de 3 nextPage por página

punteroimgVolver